Skip to main content

Ebola Virus Disease

Posts

How to Tell the Difference Between COVID-19 vs. Flu - NewYork-Presbyterian

Get link
Facebook
X
Pinterest
Email
Other Apps

- March 29, 2026

Invalid Access Key! Invalid Access Key!

Stomach Symptoms You Shouldn’t Ignore

Get link
Facebook
X
Pinterest
Email
Other Apps

- March 29, 2026

Invalid Access Key! Invalid Access Key!

Signs and Symptoms of Bird Flu in People

Get link
Facebook
X
Pinterest
Email
Other Apps

- March 29, 2026

Invalid Access Key! Invalid Access Key!

Influenza B Symptoms: Respiratory, Body, Stomach

Get link
Facebook
X
Pinterest
Email
Other Apps

- March 29, 2026

Invalid Access Key! Invalid Access Key!

Crimean-Congo haemorrhagic fever

Get link
Facebook
X
Pinterest
Email
Other Apps

- March 29, 2026

Invalid Access Key! Invalid Access Key!

Signs and Symptoms of Bird Flu in People

Get link
Facebook
X
Pinterest
Email
Other Apps

- March 28, 2026

Invalid Access Key! Invalid Access Key!

How to Tell the Difference Between COVID-19 vs. Flu - NewYork-Presbyterian

Get link
Facebook
X
Pinterest
Email
Other Apps

- March 28, 2026

Invalid Access Key! Invalid Access Key!

Powered by Blogger

Archive

March 202682
February 202620
July 202515
June 2025104
May 2025102
April 2025102
March 202593
February 2025102
January 2025105
December 202489

Show more Show less

Labels

ebola
ebola congo
ebola epidemic
ebola incubation period
ebola outbreak
Ebola Virus Disease
IFTTT
virus ebola
what is ebola

Popular Posts

Stomach Symptoms You Shouldn’t Ignore

- March 14, 2026

Invalid Access Key! Invalid Access Key!

Here’s How COVID-19 Compares to Past Outbreaks

- March 01, 2026

Invalid Access Key! Invalid Access Key!

Free biotech stocks directory, pharma stocks, telemedicine stocks ...

- March 31, 2023

cmt disease :: Article Creator Researchers Develop Technology To Treat Charcot-Marie-Tooth (CMT) Disease The research team led by Professor Minseok Kim from the Department of New Biology at DGIST (President Yang Kuk) has developed a technology that can treat Charcot-Marie-Tooth (CMT) disease, an incurable hereditary disease, with electric stimulation instead of drug therapy. This technology has considerable potential for the development of an electronic medicine with minimal side effects in the future. The core of this technology is electric stimulation that corrects the abnormal distribution of peripheral myelin protein 22 (PMP 22), the cause of the disease. The research team discovered it by conducting a series of electric stimulation experiments using a CMT disease subtype 1A (CMT1A) cell model. The study was published in the March 15 issue of the journal Biosensors and Bioelectronics. CMT disease causes muscle atrophy, numbness, foot def...

When You Should Start Taking Spring Allergy Medication - Health.com

- February 28, 2023

The arrival of spring may feel like a far-off reality depending on where in the U.S. you live, but experts say now is the time to start thinking about taking medication to protect against symptoms from springtime allergies. Seasonal allergies, also called seasonal allergic rhinitis, or hay fever, are incredibly common in the U.S.—it's estimated that the condition affects over 19 million adults and over 5 million children. And though the worst season for allergies depends on what each person is allergic to, early spring can bring heavy levels of pollen that are difficult for some people to manage. "I always tell patients, 'Start taking your go-to over-the-counter allergy tablet [on] Valentine's Day,'" Christina Cruz, MD, allergist and immunologist with Tufts Medical Center, told Health . "It gives you a couple of weeks before the pollen starts building up to have a little baseline protection." Here's what experts had to ...

Marcello Bonfanti on the frontline of Sierra Leone's Ebola epidemic

- November 24, 2018

The documentary photographer discusses the realities of shooting amid one of the world’s worst Ebola outbreaks in history During the Wellcome Photography Prize submission period, which closes 17 December 2018, British Journal of Photography is profiling photographers who are exploring the importance of health in society and the impact health issues have on people and communities worldwide. In line with the Outbreaks category , BJP spoke to Marcello Bonfanti, who took portraits of women and children Ebola-survivors in Sierra Leone. In 2014 Sierra Leone was in the grip of one of the worst outbreaks of Ebola the world has ever seen. It was clear that without a coordinated, international response, the deathly disease would become a pandemic, threatening global health security. At the time, Sierra Leone, which ranked 181st out of 188 countries in the United Nations Human Development Index (a summary measure of average achievement in key dimensions of human development) and is one ...

The Massive Effort To Halt Ebola In Congo - NPR

- August 30, 2019

[unable to retrieve full-text content] The Massive Effort To Halt Ebola In Congo NPR When Ebola spread to the eastern city of Goma in July, the World Health Organization declared the outbreak an international crisis. We look at what is being ... https://ift.tt/2ZBk6DD

Why Are People So Angry At Ebola Responders In The Democratic Republic Of The Congo?

- October 31, 2018

IntraHealth Interview Highlights Lessons From 2014 West Africa Ebola Outbreak - Kaiser Family Foundation

- November 27, 2018

IntraHealth Interview Highlights Lessons From 2014 West Africa Ebola Outbreak Nov 26, 2018 IntraHealth International’s “ VITAL ”: Getting to Zero: Lessons on Ebola and Global Health Security In this interview, Jessica Turner, Global Health Corps fellow at IntraHealth International, speaks with Oliver Johnson, coauthor of the book “Getting to Zero: A Doctor and a Diplomate on the Ebola Frontline,” about how lessons from the 2014 West Africa Ebola outbreak are informing the current outbreak in the Democratic Republic of the Congo. Turner writes, “As an international community, we have a responsibility to learn these lessons, and urge investment in and support for frontline health workers around the world. We must remember the damaging impact that politics can have on response efforts and encourage all parties to prioritize health and human life over their own agendas” (11/20). https://ift.tt/2SdbEqT

Congo starts first-ever trial testing Ebola drugs

- November 26, 2018

Posted: Nov. 26, 2018 7:00 am Updated: Nov. 26, 2018 7:23 am DAKAR, Senegal (AP) — Congo has begun the first-ever trial to test the effectiveness and safety of four experimental Ebola drugs, the first time scientists have directly compared such treatments, the World Health Organization said Monday. The U.N. health agency described the multi-drug trial as "a giant step" that would "bring clarity about what works best." "While our focus remains on bringing this outbreak to an end, the launch of the randomized control trial in DRC (Congo) is an important step toward finally finding an Ebola treatment that will save lives," said WHO Director-General Tedros Adhanom Ghebreyesus. Since the beginning of the Ebola outbreak in the North Kivu province in August, four therapeutic drugs have been used to treat patients, namely mAb 114, ZMapp, Remdesivir and Regeneron, according to Congo's Health Ministry. To date, more than 160 people have been treated with ...

HIV Drug Sunlenca (Lenacapavir) Gets FDA Approval - Everyday Health

- January 08, 2023

The U.S. Food and Drug Administration (FDA) has approved Sunlenca (lenacapavir), a new type of medication for the most common variant of HIV, HIV-1 (human immunodeficiency virus type 1). Lenacapavir is designed for heavily treatment-experienced adults with multidrug-resistant HIV who are not able to adequately manage the virus with their current treatment regimen. It is an injectable medication administered under the skin (subcutaneously) once every six months. Developed by Gilead Sciences, lenacapavir is the first of a new class of HIV medications called capsid inhibitors, which work by blocking the virus's protein shell (the capsid), thereby interfering with essential steps of the virus's life cycle. In a clinical trial, lenacapavir was able to lower the viral load in patients who were not responding adequately to other therapies. "Today's approval ushers in a new class of antiretroviral drugs that may help patients with HIV who have run out of treatment options,...